Passage Bio, Inc. (PASG)
| Market Cap | 19.25M +3.9% |
| Revenue (ttm) | n/a |
| Net Income | -37.68M |
| EPS | -11.84 |
| Shares Out | 3.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 49,353 |
| Open | 5.92 |
| Previous Close | 5.97 |
| Day's Range | 5.54 - 6.07 |
| 52-Week Range | 3.94 - 20.00 |
| Beta | 1.41 |
| Analysts | Hold |
| Price Target | 12.00 (+100.0%) |
| Earnings Date | May 12, 2026 |
About PASG
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding β-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington’s... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for PASG stock is "Hold." The 12-month stock price target is $12.0, which is an increase of 100.00% from the latest price.
News
Passage Bio Transcript: AGM 2026
The meeting covered board elections, ratification of the accounting firm, and executive compensation votes. All proposals passed, including annual advisory votes on executive pay. No questions were raised by stockholders during the Q&A.
Passage Bio Quarterly report: Q1 2026
Passage Bio has published its Q1 2026 quarterly earnings report on May 12, 2026.
Passage Bio Slides: Corporate presentation
Passage Bio has posted slides in relation to its latest quarterly earnings report, which was published on May 11, 2026.
Wedbush downgrades Passage Bio to Neutral on regulatory uncertainties
As previously reported, Wedbush analyst Yun Zhong downgraded Passage Bio (PASG) to Neutral from Outperform with a price target of $8, down from $32. The firm cites Monday’s regulatory update…
Passage Bio downgraded to Hold from Buy at TD Cowen
TD Cowen analyst Yaron Werber downgraded Passage Bio (PASG) to Hold from Buy with no price target after the company released updated Phase 1/2 frontotemporal dementia with granulin mutations data…
Passage Bio price target lowered to $15 from $30 at Oppenheimer
Oppenheimer lowered the firm’s price target on Passage Bio (PASG) to $15 from $30 and keeps an Outperform rating on the shares after the company released upliFT-D data alongside FDA…
Passage Bio downgraded to Neutral from Outperform at Wedbush
Wedbush downgraded Passage Bio (PASG) to Neutral from Outperform with a price target of $8, down from $32.
Passage Bio downgraded to Neutral from Buy at Chardan
Chardan analyst Janani Sundararajan downgraded Passage Bio (PASG) to Neutral from Buy with a $7 price target following the company’s decision to pursue strategic alternatives. The firm sees uncertaint...
Passage Bio downgraded to Neutral from Buy at Lucid Capital
Lucid Capital analyst Elemer Piros downgraded Passage Bio (PASG) to Neutral from Buy with a price target of $9, down from $68, after the company reported updated data from the…
Passage Bio reports updated interim data from upliFT-D trial
Passage Bio (PASG) reported updated data from the ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of frontotemporal dementia, FTD, with granulin mutations. In addition, t...
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels
Passage Bio Slides: Corporate presentation
Passage Bio has posted slides in relation to its latest quarterly earnings report, which was published on April 17, 2026.
Passage Bio Proxy statement: Proxy filing
Passage Bio filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.
Passage Bio Proxy statement: Proxy filing
Passage Bio filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.
Passage Bio initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Passage Bio (PASG) with an Outperform rating and $30 price target. The firm views the year-to-date pullback in shares as “an overreaction” to competitor program failu...
Passage Bio Transcript: TD Cowen 46th Annual Health Care Conference
AAV gene therapy for FTD-GRN is advancing with a focus on earlier-stage patients and a safer, lower dose, showing promising biomarker and safety data. Regulatory discussions are ongoing, and a Huntington’s program is progressing toward clinical candidate selection.
Passage Bio price target lowered to $23 from $67 at Canaccord
Canaccord analyst Whitney Ijem lowered the firm’s price target on Passage Bio (PASG) to $23 from $67 and keeps a Buy rating on the shares. The firm updated it model…
Passage Bio reports Q4 EPS ($4.09), consensus ($2.80)
“We are proud of the progress made in 2025 as we meaningfully advanced our PBFT02 clinical program for the treatment of genetic forms of frontotemporal dementia,” said Will Chou, M.D.,…
Passage Bio sees cash runway through 1Q27
Cash and cash equivalents were $46.3 million as of December 31, 2025, as compared to cash, cash equivalents, and marketable securities of $76.8 million as of December 31, 2024. The…
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study Treated first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of upliFT-D study On track to report updated interim safety...
Passage Bio Annual report: Q4 2025
Passage Bio has published its Q4 2025 annual report on March 3, 2026.
Passage Bio Annual report: Q4 2025
Passage Bio has published its Q4 2025 annual report on March 3, 2026.
Passage Bio Earnings release: Q4 2025
Passage Bio released its Q4 2025 earnings on March 3, 2026, summarizing the period's financial results.
Passage Bio Slides: Corporate presentation
Passage Bio has posted slides in relation to its latest quarterly earnings report, which was published on February 27, 2026.
Passage Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Lead gene therapy program for FTD-GRN shows robust, durable target engagement and favorable safety, with a focus on earlier-stage patients and improved trial design. Huntington's program targets MSH3, with clinical candidate selection expected in H2. Cash runway extends into Q1 2027.